International consensus guidance for management of myasthenia gravis: Executive summary

Donald B Sanders, Gil I Wolfe, Michael Benatar, Amelia Evoli, Nils E Gilhus, Isabel Illa, Nancy Kuntz, Janice M Massey, Arthur Melms, Hiroyuki Murai, Michael Nicolle, Jacqueline Palace, David P Richman, Jan Verschuuren, Pushpa Narayanaswami, Donald B Sanders, Gil I Wolfe, Michael Benatar, Amelia Evoli, Nils E Gilhus, Isabel Illa, Nancy Kuntz, Janice M Massey, Arthur Melms, Hiroyuki Murai, Michael Nicolle, Jacqueline Palace, David P Richman, Jan Verschuuren, Pushpa Narayanaswami

Abstract

Objective: To develop formal consensus-based guidance for the management of myasthenia gravis (MG).

Methods: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness methodology was used to develop consensus guidance statements. Definitions were developed for goals of treatment, minimal manifestations, remission, ocular MG, impending crisis, crisis, and refractory MG. An in-person panel meeting then determined 7 treatment topics to be addressed. Initial guidance statements were developed from literature summaries. Three rounds of anonymous e-mail votes were used to attain consensus on guidance statements modified on the basis of panel input.

Results: Guidance statements were developed for symptomatic and immunosuppressive treatments, IV immunoglobulin and plasma exchange, management of impending and manifest myasthenic crisis, thymectomy, juvenile MG, MG associated with antibodies to muscle-specific tyrosine kinase, and MG in pregnancy.

Conclusion: This is an international formal consensus of MG experts intended to be a guide for clinicians caring for patients with MG worldwide.

© 2016 American Academy of Neurology.

References

    1. Deenen JCW, Horlings CGC, Verschuuren JJGM, Verbeek ALM. The epidemiology of neuromuscular disorders: a comprehensive overview of the literature. J Neuromuscul Dis 2015;2:73–85.
    1. Grob D, Brunner NG, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008;37:141–149.
    1. Jaretzki A III, Barohn RB, Ernstoff RM, et al. . Myasthenia gravis: recommendations for clinical research standards: Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16–23.
    1. Wiendl H. Diagnostik und Therapie der Myasthenia gravis und des Lambert-Eaton-Syndroms [online]. Available at: . Accessed August 14, 2015.
    1. Fuhr P, Gold R, Hohlfeld R, et al. . Diagnostik und therapie der myasthenia gravis und des Lambert-Eaton Syndroms. In: Diener HC, Weimar C, Deuschl G, et al. eds. Leitlinien für Diagnostik und Therapie in der Neurologie, 5th ed. Stuttgart: Thieme; 2012:830–856.
    1. Murai H. Japanese clinical guidelines for myasthenia gravis: putting into practice. Clin Exp Neuroimmunol 2015;6:21–31.
    1. Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D. Myasthenia gravis: association of British Neurologists' management guidelines. Pract Neurol 2015;15:199–206.
    1. Norwood F, Dhanjal M, Hill M, et al. . Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group. J Neurol Neurosurg Psychiatry 2014;85:538–543.
    1. Skeie GO, Apostolski S, Evoli A, et al. . Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010;17:893–902.
    1. Fitch K, Bernstein SJ, Aguilar MD, et al. . The RAND/UCLA Appropriateness Method User's Manual. Santa Monica, CA: RAND Corporation; 2001.
    1. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v4.03 [online]. Available at: . Accessed May 25, 2016.
    1. US Food and Drug Administration. Pregnancy and Lactation Final Rule [online]. Available at: . Accessed November 11, 2015.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa